232 related articles for article (PubMed ID: 29537654)
1. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.
Quaife M; Terris-Prestholt F; Eakle R; Cabrera Escobar MA; Kilbourne-Brook M; Mvundura M; Meyer-Rath G; Delany-Moretlwe S; Vickerman P
J Int AIDS Soc; 2018 Mar; 21(3):. PubMed ID: 29537654
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
4. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
5. Preferences for ARV-based HIV prevention methods among men and women, adolescent girls and female sex workers in Gauteng Province, South Africa: a protocol for a discrete choice experiment.
Quaife M; Eakle R; Cabrera M; Vickerman P; Tsepe M; Cianci F; Delany-Moretlwe S; Terris-Prestholt F
BMJ Open; 2016 Jun; 6(6):e010682. PubMed ID: 27354071
[TBL] [Abstract][Full Text] [Related]
6. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
[TBL] [Abstract][Full Text] [Related]
7. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
[TBL] [Abstract][Full Text] [Related]
8. HIV prevention is not all about HIV - using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection.
Vickerman P; Quaife M; Kilbourne-Brook M; Mvundura M; Eakle R; Terris-Prestholt F
BMC Infect Dis; 2020 Sep; 20(1):704. PubMed ID: 32977745
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of the dual prevention pill for contraception and HIV pre-exposure prophylaxis.
Milali MP; Resar D; Kaftan D; Campbell J; Olowu A; Edwards D; Platais I; Kim HY; Jenkins S; Bershteyn A
Front Reprod Health; 2023; 5():1144217. PubMed ID: 37266447
[TBL] [Abstract][Full Text] [Related]
10. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
11. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
[TBL] [Abstract][Full Text] [Related]
12. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis.
Stone J; Bothma R; Gomez GB; Eakle R; Mukandavire C; Subedar H; Fraser H; Boily MC; Schwartz S; Coetzee J; Otwombe K; Milovanovic M; Baral S; Johnson LF; Venter WDF; Rees H; Vickerman P
J Int AIDS Soc; 2023 Feb; 26(2):e26063. PubMed ID: 36807874
[TBL] [Abstract][Full Text] [Related]
13. Preferences, educational messaging, and demand creation channels for multipurpose-prevention technologies (MPTs) among women in South Africa.
Mataboge P; Mthimkhulu N; Kutywayo A; Martin CE; Mazibuko M; Kwatsha K; Makalela N; Briedenhann E; Butler V; Bothma R; Mullick S
BMC Public Health; 2023 Oct; 23(1):2090. PubMed ID: 37880628
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices.
Terris-Prestholt F; Foss AM; Cox AP; Heise L; Meyer-Rath G; Delany-Moretlwe S; Mertenskoetter T; Rees H; Vickerman P; Watts CH
BMC Infect Dis; 2014 Jan; 14():14. PubMed ID: 24405719
[TBL] [Abstract][Full Text] [Related]
15. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa.
Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Kilbourne-Brook M; Mvundura M; Delany-Moretlwe S; Terris-Prestholt F
Med Decis Making; 2018 Jan; 38(1):120-133. PubMed ID: 28863752
[TBL] [Abstract][Full Text] [Related]
16. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa.
Jamieson L; Gomez GB; Rebe K; Brown B; Subedar H; Jenkins S; Shoko N; Bekker LG; Johnson LF; Meyer-Rath G
AIDS; 2020 May; 34(6):883-891. PubMed ID: 32004205
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.
Price JT; Wheeler SB; Stranix-Chibanda L; Hosek SG; Watts DH; Siberry GK; Spiegel HM; Stringer JS; Chi BH
J Acquir Immune Defic Syndr; 2016 Aug; 72 Suppl 2(Suppl 2):S145-53. PubMed ID: 27355502
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Introducing the SILCS Diaphragm in South Africa.
Lépine A; Nundy N; Kilbourne-Brook M; Siapka M; Terris-Prestholt F
PLoS One; 2015; 10(8):e0134510. PubMed ID: 26295955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
